• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for HUMIRA issued to ABBVIE INC

    11/6/23 4:38:34 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    Biologic License Application (BLA): 125057
    Company: ABBVIE INC
    • Email
    • Medication Guide
    • Summary Review
    • Other Important Information from FDA

    Products on BLA 125057

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    HUMIRA ADALIMUMAB 40MG/0.8ML SYRINGE Prescription None No No
    HUMIRA ADALIMUMAB 40MG/0.8ML VIAL Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 125057

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    12/31/2002 ORIG-1 Approval N/A; Orphan Label
    Letter
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/adalabb123102LB.htm https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    11/03/2023 SUPPL-423 Supplement

    Label is not available on this site.

    12/16/2020 SUPPL-419 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s418s419lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125057Orig1s418, s419ltr.pdf
    12/16/2020 SUPPL-418 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s418s419lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125057Orig1s418, s419ltr.pdf
    02/24/2021 SUPPL-417 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125057Orig1s417ltr.pdf
    03/11/2020 SUPPL-415 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125057Orig1s415ltr.pdf
    01/11/2019 SUPPL-411 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125057Orig1s411lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/125057Orig1s411ltr.pdf
    12/06/2018 SUPPL-410 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125057s410ltr.pdf
    10/16/2018 SUPPL-409 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s409lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125057Orig1s409ltr.pdf
    09/28/2018 SUPPL-408 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s408lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125057Orig1s408ltr.pdf
    08/02/2018 SUPPL-406 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s406lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125057Orig1s406ltr.pdf
    12/14/2017 SUPPL-403 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s403lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125057Orig1s403ltr.pdf
    04/28/2017 SUPPL-402 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s402lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125057Orig1s402ltr.pdf
    04/21/2017 SUPPL-401 Supplement Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s401lbl.pdf
    10/17/2016 SUPPL-400 Supplement Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125057s400lbl.pdf
    03/27/2017 SUPPL-399 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s399lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125057Orig1s399ltr.pdf
    06/30/2016 SUPPL-397 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125057s397lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/125057Orig1s397ltr.pdf
    11/23/2015 SUPPL-394 Supplement Label (PDF)
    Letter (PDF)
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125057s394lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125057Orig1s394ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125057Orig1s394SumR.pdf
    09/09/2015 SUPPL-393 Supplement Letter (PDF)
    Review (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125057Orig1s393ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125057Orig1s393.pdf
    11/06/2014 SUPPL-390 Supplement

    Label is not available on this site.

    10/29/2014 SUPPL-384 Supplement

    Label is not available on this site.

    08/07/2014 SUPPL-381 Supplement Review (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/bla/2014/125057Orig1s381.pdf
    05/14/2014 SUPPL-368 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s368lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125057Orig1s368ltr.pdf
    09/30/2014 SUPPL-367 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125057Orig1s367ltr.pdf
    05/30/2014 SUPPL-366 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s366lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125057Orig1s366ltr.pdf
    09/23/2014 SUPPL-356 Supplement Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s356lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125057Orig1s356ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125057Orig1s356.pdf
    02/26/2014 SUPPL-355 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057Orig1s355lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125057Orig1s355_replace_ltr.pdf
    09/19/2013 SUPPL-327 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s327lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125057Orig1s327ltr.pdf
    04/24/2013 SUPPL-322 Supplement Label (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s322lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125057Orig1s322.pdf
    05/13/2013 SUPPL-310 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s310lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125057Orig1s310ltr.pdf
    12/24/2014 SUPPL-280 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125057Orig1s280ltr.pdf
    05/24/2012 SUPPL-278 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125057s0278lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/125057s0278ltr.pdf
    12/26/2011 SUPPL-276 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125057s276ltr.pdf
    12/13/2011 SUPPL-271 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/125057s271ltr.pdf
    09/07/2011 SUPPL-255 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125057s255ltr.pdf
    07/13/2011 SUPPL-254 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125057s254ltr.pdf
    09/28/2012 SUPPL-232 Supplement Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125057s232lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/125057Orig1s232ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125057Orig1s232.pdf
    09/29/2010 SUPPL-224 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/125057s224ltr.pdf
    02/25/2011 SUPPL-215 Supplement Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0215lbl.pdf
    07/29/2010 SUPPL-213 Supplement Letter (PDF)
    Review (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/125057s0213ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/bla/2010/125057Orig1s0213.pdf
    11/18/2010 SUPPL-196 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125057s196lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/125057s0196ltr.pdf
    04/08/2010 SUPPL-161 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/125057s161ltr.pdf
    03/11/2009 SUPPL-141 Supplement

    Label is not available on this site.

    03/14/2011 SUPPL-128 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125057s128ltr.pdf
    02/21/2008 SUPPL-114 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s114ltr.pdf
    01/18/2008 SUPPL-110 Supplement Label (PDF)
    Letter (PDF)
    Review
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s0110ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125057s110_SumR.pdf
    09/05/2007 SUPPL-108 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s108lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/125057s108_ltr.pdf
    11/09/2006 SUPPL-95 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s071, s095LBL.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/125057s071, s095LTR.pdf
    07/30/2007 SUPPL-94 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s094_LBL.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/125057s094ltr.pdf
    02/27/2007 SUPPL-89 Supplement Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s089Lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/125057s089Ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/bla/2007/125057_S0089.pdf
    11/09/2006 SUPPL-71 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s071, s095LBL.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/125057s071, s095LTR.pdf
    06/23/2006 SUPPL-65 Supplement

    Label is not available on this site.

    07/28/2006 SUPPL-62 Supplement Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s062lbl.pdf
    02/16/2007 SUPPL-60 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s060LBL.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/125057s060LTR.pdf
    10/03/2005 SUPPL-46 Supplement Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/125057s0045,0046lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/125057s0046ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/bla/2005/125057Orig1s046.pdf
    10/03/2005 SUPPL-45 Supplement Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/125057s0045,0046lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/125057s0045ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/bla/2005/125057Orig1s045.pdf
    06/18/2004 SUPPL-23 Supplement Letter (PDF)
    Review (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/125057_0023ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125057Orig1s023.pdf
    07/30/2004 SUPPL-16 Supplement Label (PDF)
    Letter (PDF)
    Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125057_0016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/125057_0016ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125057Orig1s016.pdf
    09/12/2003 SUPPL-4 Supplement

    Label is not available on this site.

    Labels for BLA 125057

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    02/24/2021 SUPPL-417 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf
    12/16/2020 SUPPL-419 Efficacy-New Dosing Regimen Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s418s419lbl.pdf
    12/16/2020 SUPPL-418 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s418s419lbl.pdf
    03/11/2020 SUPPL-415 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf
    01/11/2019 SUPPL-411 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125057Orig1s411lbl.pdf
    12/06/2018 SUPPL-410 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf
    10/16/2018 SUPPL-409 Efficacy-New Dosing Regimen Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s409lbl.pdf
    09/28/2018 SUPPL-408 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s408lbl.pdf
    08/02/2018 SUPPL-406 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s406lbl.pdf
    12/14/2017 SUPPL-403 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s403lbl.pdf
    04/28/2017 SUPPL-402 Manufacturing (CMC) Label (PDF) This supplement type does not usually require new labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s402lbl.pdf
    04/21/2017 SUPPL-401 Labeling-Medication Guide Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s401lbl.pdf
    03/27/2017 SUPPL-399 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s399lbl.pdf
    10/17/2016 SUPPL-400 Manufacturing (CMC)-Control Label (PDF) This supplement type does not usually require new labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125057s400lbl.pdf
    06/30/2016 SUPPL-397 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125057s397lbl.pdf
    11/23/2015 SUPPL-394 Efficacy-Manufacturing Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125057s394lbl.pdf
    09/30/2014 SUPPL-367 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf
    09/23/2014 SUPPL-356 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s356lbl.pdf
    05/30/2014 SUPPL-366 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s366lbl.pdf
    05/14/2014 SUPPL-368 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s368lbl.pdf
    02/26/2014 SUPPL-355 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057Orig1s355lbl.pdf
    09/19/2013 SUPPL-327 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s327lbl.pdf
    05/13/2013 SUPPL-310 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s310lbl.pdf
    04/24/2013 SUPPL-322 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s322lbl.pdf
    09/28/2012 SUPPL-232 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125057s232lbl.pdf
    05/24/2012 SUPPL-278 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125057s0278lbl.pdf
    12/26/2011 SUPPL-276 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf
    02/25/2011 SUPPL-215 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0215lbl.pdf
    11/18/2010 SUPPL-196 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125057s196lbl.pdf
    02/21/2008 SUPPL-114 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf
    01/18/2008 SUPPL-110 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf
    09/05/2007 SUPPL-108 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s108lbl.pdf
    07/30/2007 SUPPL-94 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s094_LBL.pdf
    02/27/2007 SUPPL-89 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s089Lbl.pdf
    02/16/2007 SUPPL-60 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125057s060LBL.pdf
    11/09/2006 SUPPL-95 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s071, s095LBL.pdf
    11/09/2006 SUPPL-71 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s071, s095LBL.pdf
    07/28/2006 SUPPL-62 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s062lbl.pdf
    10/03/2005 SUPPL-46 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/125057s0045,0046lbl.pdf
    10/03/2005 SUPPL-45 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/125057s0045,0046lbl.pdf
    07/30/2004 SUPPL-16 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125057_0016lbl.pdf
    12/31/2002 ORIG-1 Approval https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/adalabb123102LB.htm
    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    10/1/2025Buy → Hold
    HSBC Securities
    9/17/2025$270.00Hold → Buy
    Berenberg
    More analyst ratings

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

    The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences.Natrelle® champions women's voices to provide support at every step of their breast aesthetics journey.IRVINE, Calif., Feb. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the launch of the Faces of Natrelle® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle® breast implants to help educate, empower, and support others considering breast surgery.

    2/3/26 8:50:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:15 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:18 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    1/5/26 5:00:10 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on AbbVie with a new price target

    UBS resumed coverage of AbbVie with a rating of Neutral and set a new price target of $240.00

    1/7/26 9:08:42 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $265.00

    12/10/25 8:10:03 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    2/4/26 7:54:33 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    1/7/26 4:08:59 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by AbbVie Inc.

    10-Q - AbbVie Inc. (0001551152) (Filer)

    11/4/25 2:05:49 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t

    1/7/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Third-Quarter 2025 Financial Results

    Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues

    10/31/25 7:49:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care